Action FACT II Acquisition - FACT

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

9,97

Prix Achat

9,88

Prix Vente

10,04

Volume échangé

118

9,97 Fourchette du Jour 9,97

9,85 Plage de 52 semaines 27,01

Clôture Veille

9,97

Ouverture

9,97

Dernière Transaction

9.95

Dernière heure de transaction

Volume moyen (3 m)

49 403

Volume financier

VWAP

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation PR Newswire INCLINE VILLAGE, Nev., March 24 INCLINE VILLAGE, Nev., March...

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Facet Biotech Corporation by Abbott Laboratories

Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of...

Kendall Law Group Investigates Facet Biotech Corporation Merger for Shareholders

Kendall Law Group, a national securities litigation firm is investigating Facet Biotech Corporation (NASDAQ: FACT) for...

Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Facet Biotech Corporation

Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of Facet...

Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Facet Biotech Corporation - FACT

Levi & Korsinsky is investigating the Board of Directors of Facet Biotech Corporation (“Facet Biotech” or the “Company”...

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott and Facet Biotech Corporation announced today a definitive...

Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors

SAN FRANCISCO, Jan. 11 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage cancer biotherapeutics company...

Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting

SEATTLE and REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (NASDAQ:TRBN) and Facet Biotech Corp...

Facet Biotech & Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multip...

Facet Biotech Corporation (Nasdaq: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	9.97	10.0507	9.945	131656	9.954598	CS
4	0.06	0.605449041372	9.91	10.0507	9.91	51636	9.94911137	CS
12	-17.04	-63.0877452795	27.01	27.01	9.85	49403	9.91012994	CS
26	-17.04	-63.0877452795	27.01	27.01	9.85	21565	9.91012994	CS
52	-17.04	-63.0877452795	27.01	27.01	9.85	10869	9.91012994	CS
156	-17.04	-63.0877452795	27.01	27.01	9.85	3604	9.91012994	CS
260	-17.04	-63.0877452795	27.01	27.01	9.85	2481	9.91012994	CS

FACT - Frequently Asked Questions (FAQ)

What is the current FACT II Acquisition share price?

The current share price of FACT II Acquisition is US$ 9,97

What is the 1 year trading range for FACT II Acquisition share price?

FACT II Acquisition has traded in the range of US$ 9,85 to US$ 27,01 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
JTAIJet AI Inc	US$ 6,02 (133,33%)	104,48M
SRMSRM Entertainment Inc	US$ 0,6999 (95,50%)	254,39M
WRDWeRide Inc	US$ 31,4877 (83,39%)	21,07M
INLFINLIF Limited	US$ 16,27 (80,58%)	7,68M
MBRXMoleculin Biotech Inc	US$ 2,1201 (66,94%)	136,66M
BLACBellevue Life Sciences Acquisition Corporation	US$ 3,08 (-56,31%)	430,77k
BLACUBellevue Life Sciences Acquisition Corporation	US$ 3,36 (-52,68%)	5,21k
CSAICloudastructure Inc	US$ 19,0001 (-49,58%)	1,03M
NEXNNexxen International Ltd	US$ 10,30 (-49,16%)	164,82k
BSLKBolt Projects Holdings Inc	US$ 0,6626 (-46,13%)	13,4M
CNSPCNS Pharmaceuticals Inc	US$ 0,1415 (31,26%)	489,28M
MGOLMGO Global Inc	US$ 0,7176 (-15,08%)	417,31M
SRMSRM Entertainment Inc	US$ 0,6999 (95,50%)	254,39M
INTCIntel Corporation	US$ 23,60 (-2,20%)	230,26M
NVDANVIDIA Corporation	US$ 138,85 (2,63%)	194,99M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

FACT II Acquisition Corporation (FACT)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

FACT Dernières nouvelles

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Facet Biotech Corporation by Abbott Laboratories

Kendall Law Group Investigates Facet Biotech Corporation Merger for Shareholders

Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Facet Biotech Corporation

Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Facet Biotech Corporation - FACT

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors

Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting

Facet Biotech & Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multip...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

FACT - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

FACT II Acquisition Corporation (FACT) Cours

FACT II Acquisition Corporation (FACT)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

FACT Dernières nouvelles

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

PDL BioPharma Clarifies $13.00 Cost Basis in Facet Biotech Corporation

Bull & Lifshitz, LLP Announces Investigation of the Acquisition of Facet Biotech Corporation by Abbott Laboratories

Kendall Law Group Investigates Facet Biotech Corporation Merger for Shareholders

Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of Facet Biotech Corporation

Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Facet Biotech Corporation - FACT

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

Jennerex Appoints Dr. Hoyoung Huh to Its Board of Directors

Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting

Facet Biotech & Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab in Patients with Relapsed Multip...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

FACT - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités